SCHEMBL21312797

SCHEMBL21312797

c1cnc2cc(-c3cnc4cc(-c5cnc6cc[nH]c6c5)sc4c3)oc2c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.38
▸ PIK3C3 Q8NEB9 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.31
▸ CHRNB2 P17787 1/20 0.30
▸ CHRNA4 P43681 1/20 0.30
▸ ADRA2A P08913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24447710 0.88 BRD4 (0.47) BRD4PIK3C3CHRM2CHRM4CHRM5
SCHEMBL24067772 0.83 BRD4 (0.47) BRD4PIK3C3LRRK2
SCHEMBL25515225 0.73 BRD4 (0.37) BRD4PIK3C3LRRK2
SCHEMBL21191611 0.66 ALOX5AP (0.35) BRD4CHRM2CHRM4CHRM5CHRM1
SCHEMBL28428414 0.65 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL9430009 0.64 CYP1B1 (0.50) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL23418544 0.63 ABCB1 (0.38) KDM4ENPC1ALDH1A1HPGDRAB9A
SCHEMBL31283847 0.63 CHRM2 (0.43) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL18648069 0.62 RIPK1 (0.35) —
SCHEMBL15730145 0.62 BRD4 (0.53) BRD4PIK3C3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371433-A1 Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 — — US disclosed
US-20190263833-A1 NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263833-A1 NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT8 BRD4 50/4885PIK3C3 1638/4885CHRM2 1972/4885
US-20210371433-A1 Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors PRMT5, PRMT1, PRMT8 BRD4 55/4885PIK3C3 1702/4885CHRM2 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback